Vilin Bio Med

Vilin Bio Med EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vilin Bio Med (VILINBIO.NS) as of Nov 4, 2026 is 7.66 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 8.57 M INR — a change of -10.58% (lower).

EBITDA

7.66 MINR

YoY

-10.58%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vilin Bio Med is 2022 7.66 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vilin Bio Med was 2021 8.57 M INR. It decreases by -10.58% lower compared to the previous year.

The Vilin Bio Med EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
8.99 M INR
Jan 1, 2021
8.57 M INR
Jan 1, 2022
7.66 M INR
The Vilin Bio Med EBITDA history
YEAREBITDAYoY
7.66 MINR-10.58%
8.57 MINR-4.74%
8.99 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vilin Bio Med Stock analysis

What does Vilin Bio Med do? Vilin Bio Med Ltd manufactures pharmaceutical products including solid oral dosage forms such as Cefixime, Azithromycin, and Sulmtmicilline, along with oral liquids, external preparations, and dry powders. The company's beta-lactam products treat bacterial infections, while non-beta-lactam products address conditions like colds, flu, fever, and antimalarial needs. Its external preparations include ointments, creams, lotions, gels, and pates for skin applications. The firm focuses on domestic manufacturing within India, serving the local market with a diverse product portfolio. The company's product categories target various medical conditions, with beta-lactam medicines specifically for bacterial infections and non-beta-lactam products for general ailments. Its external preparations cater to topical skin treatments, offering formulations like ointments and creams. Vilin Bio Med Ltd operates as a domestic manufacturer, producing pharmaceuticals for the Indian market without international expansion mentioned in the description. Vilin Bio Med Ltd's product range includes specific medications such as Aceclofenac, Citicolin Sodium, Metformine, Pregabaline, Gabapentin, Diclofenac Sodium, Thiocolchicoside, Linseed Oil, Menthol, and Methyl Salcilate, which support its positioning in the pharmaceutical sector. The company's focus on domestic manufacturing ensures its products are tailored to local healthcare needs, with no indication of export activities or international partnerships. Vilin Bio Med is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vilin Bio Med stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vilin Bio Med is 7.66 M INR in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vilin Bio Med changed from 8.57 M INR to 7.66 M INR, representing a -10.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Vilin Bio Med since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Vilin Bio Med historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Vilin Bio Med

All Key Metrics — Vilin Bio Med